Figure 3

BMS-204352 effects on Emotionality and Spatial memory. (a) Percentage of time spent in open arms time in the elevated plus maze was calculated as the time in open arms/all arms x100. Analysis indicated a main effect of genotype, but no difference between genotypes and treatments was observed. (b) Time spent in the extremity of open arms was also evaluated and showed that Fmr1 KO mice exhibited reduced non-social anxiety in comparison to WT mice. This was corrected by BMS-204352 treatment that increased anxiety in both genotypes. *p < 0.05 (n: WT-veh = 32; WT-2 mg/kg = 7; KO-veh = 32; KO-2 mg/kg = 10). (c) Preference index for a novel arm in the Y-maze was determined by the time spent in the novel arm/ time spent in all 3 arms. Fmr1 KO mice presented spatial memory impairments through their incapacity to distinguish between novel and familiar arms. BMS-204352 treatment restored this cognitive defect to WT level. Significance was determined using two-way ANOVA with post-hoc PLSD test. NS, not significant; *p < 0.05, vs. WT; ^#p < 0.05 vs. KO-veh (n: WT-veh = 7; WT-2 mg/kg = 6; KO-veh = 7; KO-2 mg/kg = 7). Data represent mean ± s.e.m.